{"id":3237,"date":"2011-02-18T09:31:36","date_gmt":"2011-02-18T14:31:36","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=3237"},"modified":"2011-02-18T09:31:36","modified_gmt":"2011-02-18T14:31:36","slug":"contract-awarded-for-smallpox-countermeasure-drug-candidate","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=3237","title":{"rendered":"Contract Awarded for Smallpox Countermeasure Drug Candidate"},"content":{"rendered":"<figure id=\"attachment_3239\" aria-describedby=\"caption-attachment-3239\" style=\"width: 275px\" class=\"wp-caption alignright\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/SmallpoxVax_CDCgov.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-3239\" title=\"SmallpoxVax_CDCgov\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/SmallpoxVax_CDCgov.jpg\" alt=\"Small pox vaccination (CDC.gov)\" width=\"275\" height=\"199\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/SmallpoxVax_CDCgov.jpg 275w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/SmallpoxVax_CDCgov-150x108.jpg 150w\" sizes=\"auto, (max-width: 275px) 100vw, 275px\" \/><\/a><figcaption id=\"caption-attachment-3239\" class=\"wp-caption-text\">(CDC.gov)<\/figcaption><\/figure>\n<p>Chimerix Inc., a pharmaceutical company in Research Triangle Park, North Carolina, was <a href=\"http:\/\/www.chimerix-inc.com\/news-and-resources\/news-and-resources-details\/barda-contract\/\">awarded a contract<\/a> by the Biomedical Advanced Research and Development Authority (BARDA) to develop the company&#8217;s antiviral drug candidate, CMX001 as a medical countermeasure in the event of a smallpox release. The contract has a total potential value of $81 million.<\/p>\n<p>CMX001 is a potential therapeutic with test results showing the ability to combat all five families of double-stranded DNA (dsDNA) viruses, including smallpox. The BARDA contract will fund expanded human safety trials and a new clinical study of CMX001 for the treatment of twelve life-threatening or serious conditions caused by dsDNA viruses.<\/p>\n<p>This award is Chimerix\u2019s first contract with BARDA. Under the contract, Chimerix will receive funding of $24.8 million during the first year with subsequent option periods that, if completed, would bring the total contract value to $81.1 million.<\/p>\n<p>Read more: <a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=1487\">BARDA Awards Contract for Smallpox Antiviral Drug<\/a><\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chimerix Inc., a pharmaceutical company in Research Triangle Park, North Carolina, was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to develop the company&#8217;s antiviral drug candidate, CMX001 as a medical countermeasure in the event of a smallpox release. The contract has a total potential value of $81 million. CMX001 is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,15],"tags":[31,28,80,64,27],"class_list":["post-3237","post","type-post","status-publish","format-standard","hentry","category-finance","category-products","tag-biomedical","tag-clinical-trials","tag-contract","tag-life-sciences","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3237"}],"version-history":[{"count":2,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3237\/revisions"}],"predecessor-version":[{"id":3240,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3237\/revisions\/3240"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}